Phyton Biotech (PB), an affiliate of Phyton, has purchased the assets of Natural Pharmaceuticals (NPI). Under the terms of the agreement, PB will acquire assets of NPI, which include intellectual property and patents for the production of taxane API’s, a fully-staffed cGMP manufacturing facility in Delta, BC, Canada, and an API manufacturing subsidiary in Shanghai, China, Syntax Biotechnology.
Reportedly, PB will be contributing sufficient capital to sustain and grow the business as well as management oversight for the new company. The new organisation will unite Phyton affiliate, PB GmbH with NPI’s proprietary downstream synthesis of paclitaxel, docetaxel, and additional API’s.
Moreover, in near term the company will focus on integrating NPI and PB from infrastructure and organisational standpoints, along with increasing the output of paclitaxel and docetaxel API’s to meet the growing market demand.
Paul Johnson, president of Phyton, said: “The synergies from combining both NPI and Phyton’s proprietary and patented technologies were very apparent to us and will make the new organisation a solid force in the Taxane API market.”
Roland Franke, CEO of NPI, said: “The fusion with NPI makes Phyton Biotech the API company that produces semi-synthetic Taxanes without depending on biomass from tree plantations. The combination of plant cell fermentation and innovative manufacturing technology creates enormous capacity up front, and potential in the world-wide Taxane API market.”